Anti-Androgen Receptor Signaling and Prostate Cancer Inhibitory Effects of Sucrose- and Benzophenone-Compounds
- 204 Downloads
Novel agents that target multiple aspects of androgen receptor (AR) signaling are desirable for chemoprevention and treatment of prostate cancer (PCa). We aimed to identify compounds isolated from medicinal herbs as such drug candidates.
In the LNCaP human androgen sensitive PCa cell model, we tested five compounds purified from Lindera fruticosa Hemsley in the range of 10–50 μM for growth inhibition and AR-prostate specific antigen (PSA) suppressing potency. We determined the relationship between these activities and P53 tumor suppressor protein activation and apoptotic cleavage of PARP. We compared these compounds to the anti-androgen drug Casodex/bicalutamide to identify mechanistic novelty.
Among 3 sucrose compounds, beta-D-(3,4-di-sinapoyl)fructofuranosyl-alpha-D-(6-sinapoyl)glucopyranoside decreased AR and PSA mRNA and protein levels in LNCaP cells and inhibited androgen-stimulated AR translocation from the cytosol to the nucleus. This compound also increased P53 Ser15 phosphorylation and PARP cleavage in LNCaP cells, but required higher dosage than for suppressing AR-PSA. Interestingly, this compound did not inhibit the growth of RWPE-1 non-transformed prostate epithelial cells. The benzophenone compound 2-methoxy-3,4-(methylenedioxy)benzophenone suppressed PSA and AR in LNCaP cells without apoptosis.
Our data support novel anti-AR actions of these herbal compounds distinct from Casodex and merit further investigation as drug candidates.
KEY WORDSandrogen receptor benzophenone prostate cancer PSA sucrose derivatives
This work was supported in part by The Hormel Foundation, Prostate Cancer Foundation, by MRC grant R13-2007-019-00000-0 from Korea Ministry of Education, Science and Technology. The authors thank Todd Schuster for performing flow cytometry analyses.
Conflict of interest statements
All authors have no personal or financial conflict of interest and have not entered into any agreement that could interfere with our access to the data on the research or on our ability to analyze the data independently, to prepare manuscripts and to publish them.
- 4.G. Andriole, N. Bruchovsky, L. W. Chung et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 172(4 Pt 1):1399–1403 (2004) Oct. doi:10.1097/01.ju.0000139539.94828.29.PubMedCrossRefGoogle Scholar
- 6.C. Jiang, H. J. Lee, G. X. Li et al.. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res. 66(1):453–463 (2006) Jan 1. doi:10.1158/0008-5472.CAN-05-1865.PubMedCrossRefGoogle Scholar
- 10.C. Costa, A. Bertazzo, G. Allegri, O. Curcuruto, and P. Traldi. Indole Alkaloids from the Roots of an African Plant Securidaca Longipedunculata. I. Isolation by column chromatography and preliminary structural characterization by mass spectrometry. J. Heterocyc. Chem. 29:1641–1647 (1992).CrossRefGoogle Scholar
- 22.K. Kuratsukuri, K. Sugimura, K. Harimoto, H. Kawashima, and T. Kishimoto. “Decoy” of androgen-responsive element induces apoptosis in LNCaP cells. Prostate. 41(2):121–126 (1999) Oct 1. doi:10.1002/(SICI)1097-0045(19991001)41:2<121::AID-PROS6>3.0.CO;2-Q.PubMedCrossRefGoogle Scholar